


**Diagramma schematico della struttura della corteccia surrenalica**




**Rappresentazione schematica del sistema di vascolarizzazione della ghiandola surrenale**


LDL
HDL
StAR
CHOLESTEROL
Cholesterol side chain cleavage
PREGNENOLONE
3β-hydroxysteroid dehydrogenase
PROGESTERONE
21 hydroxylase
DOC
11β-hydroxylase
CORTICOSTERONE
Aldosterone synthase
ALDOSTERONE
MINERALOCORTICOID
17α-hydroxylase/ 17,20 lyase
17-OH-PREGNENOLONE
3β-hydroxysteroid dehydrogenase
17-OH-PROGESTERONE
21 hydroxylase
11-DEOXYCORTISOL
11β-hydroxylase
CORTISOL
GLUCOCORTICOID
17α-hydroxylase/ 17,20 lyase
DHEA
A'DIONE
ANDROGENS


Circadian regulation
Stressors (hypoglycemia, hypotension, surgery, fever, injury)
Hypothalamus
CRH
Vasopressin
Pro-inflammatory cytokines
ACTH
Adrenals
Cortisol




**Figure 7–26.** Regulation of the hypothalamic-pituitary-adrenal axis. ACTH, adrenocorticotropic hormone; AVP, arginine vasopressin; BST, bed nucleus of the stria terminalis; CNS, central nervous system; CRH, corticotropin-releasing hormone; CRIF, corticotropin release–inhibiting factor; GABA, γ-aminobutyric acid; 5-HT, 5-hydroxytryptamine; IL-1, interleukin-1; MeA, medial amygdala; MePO, medial preoptic; NPY, neuropeptide Y; NTS, nucleus of the tractus solitarius; OVLT, organum vasculosum of the lamina terminalis; POMC, pro-opiomelanocortin.




**Figure 14–5.** Synthesis and cleavage of pro-opiomelanocortin (POMC) within the human anterior pituitary gland. Prohormone convertase enzymes sequentially cleave POMC to adrenocorticotropic hormone (ACTH). *Shaded areas* represent melanocyte-stimulating hormone (MSH) structural units. β-LPH, β-lipoprotein; γ-LPH, γ-lipoprotein; N-POC, amino-terminal pro-opiomelanocortin.




**Ritmo circadiano e secrezione pulsatile di cortisolo e ACTH in condizioni normali ed in un paziente con malattia di Cushing**

## Dissociazione della secrezione di androgeni surrenalici e glucocorticoidi. Prove a supporto dell'ipotesi dell'esistenza di un ormone stimolante gli androgeni

**Desametasone:** Soppressione completa del cortisolo con alte dosi di desametasone.
DHEA si riduce di solo il 20-30%

**Adrenarca:** Aumento dei livelli di DHEA a 6-8 anni.
La produzione di cortisolo rimane inalterata.

**Invecchiamento:** Riduzione della produzione di DHEA, cortisolo non cambia

**Anoressia nervosa:** Riduzione del DHEA,
cortisolo non cambia (o aumenta)


↑K
↑BP
A II + A III
A II
ALDO
ACE
Lung
A I
Renin substrate
Liver
↑Renin
↑Na ↓K
↑Blood volume
↓Renal blood flow
↓Na+
↑K+

**Table 15–1.** *Amino Acid Composition of Angiotensin Peptides*

| | |
|---|---|
| AI | Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu |
| AII | Asp-Arg-Val-Tyr-Ile-His-Pro-Phe |
| A1-7 | Asp-Arg-Val-Tyr-Ile-His-Pro |
| AIII | Arg-Val-Tyr-Ile-His-Pro-Phe |
| AIV | Val-Tyr-Ile-His-Pro-Phe |

A, angiotensin.




**Figure 14–9.** Schematic structure of the human genes encoding the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). In both cases splice variants have been described; in the case of the GR, there is evidence that the GR$\beta$ isoform can act as a dominant negative inhibitor of GR$\alpha$ action. mRNA, messenger ribonucleic acid.


Cortisol
NUCLEUS
Cytokines
NFκB
2
GR
GR
IκB
Coactivator complex
Coactivator complex
3
-
+
HSP
C-fos
C-jun
GR
GR
HSP
CGTACAnnnTGTACT
Inflammatory response
(TNFα, IL-1β, IL-6,
IL-8, MCSF)
1
+
IκB
IκB
CELL MEMBRANE


Na+
ENaC
SGK
K-Ras
regulatory proteins ↑
structural protein ↑
MR
cortisol
11β-HSD2
cortisone
MR
K+
K+
Na+
Na+
Aldosterone

# POTENZA BIOLOGICA RELATIVA DEGLI STEROIDI SINTETICI

| Steroide | Azione anti-infiammatoria | Soppressione asse Ipot-ipof | Azione mineralcort. |
|---|---|---|---|
| Cortisolo = Idrocortisone | 1 | 1 | 1 |
| Prednisolone | 3 | 4 | 0.75 |
| Metilprednisolone | 6.2 | 4 | 0.5 |
| Fludrocortisone | 14 | 12 | 225 |
| Triamcinolone | 5 | 4 | 0 |
| Desametasone | 26 | 17 | 0 |

# Ipertensione arteriosa

| Essenziale | Da Causa endocrina |
| --- | --- |
| | Iperaldosteronismo |
| | Feocromocitoma |
| | S.Cushing |
| | Patologia tiroidea |
| | Acromegalia |
| | Iperparatiroidismo |

# Alcuni concetti di base

Vi è una sola condizione per cui vale la pena di pensare ad uno screening in pazienti ipertesi in assenza di altri segni o sintomi:

## Iperaldosteronismo primitivo

ca. 11% dei casi di ipertensione arteriosa sono dovuti ad un iperaldosteronismo

per gli effetti negativi cardiologici dell'iperaldosteronismo

causa potenzialmente risolvibile di ipertensione arteriosa

# CAUSE DI IPERALDOSTERONISMO PRIMITIVO

| | |
|---|---|
| Adenoma aldosterone-secernente (raramente carcinoma) | 65% |
| Iperaldosteronismo idiopatico (iperplasia bilaterale semplice, micro o macronodulare) | 30-40% |
| Iperaldosteronismo sopprimibile con glucocorticoidi (F. familiare I) | 1-3% |
| Secrezione ectopica di aldosterone | Raro |
| Associazione a MEN I<br>(F. familiare II) | Rara |

# QUADRO CLINICO DELL'IPERALDOSTERONISMO

- Ipertensione arteriosa di grado variabile
- Assenza di edemi
- Ipokaliemia
  - Astenia muscolare, facile stancabilità
  - Alcalosi ipokaliemica (tetania)
  - Nefropatia ipokaliemica (poliuria da danno tubulare)
  - Segni elettrocardiografici (alterazioni dell'onda T, comparsa dell'onda U, extrasistolia, fibrillazione ventricolare)

# IPOKALIEMIA…

## criterio indispensabile per sospettare iperaldosteronismo?

Journal of the American College of Cardiology
© 2006 by the American College of Cardiology Foundation
Published by Elsevier Inc.

Vol. 48, No. 11, 2006
ISSN 0735-1097/06/$32.00
doi:10.1016/j.jacc.2006.07.059

**Hypertension**

# A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients

Gian Paolo Rossi, MD, FACC, FAHA, Giampaolo Bernini, MD, Chiara Caliumi, MD, Giovambattista Desideri, MD, Bruno Fabris, MD, Claudio Ferri, MD, Chiara Ganzaroli, MD, Gilberta Giacchetti, MD, Claudio Letizia, MD, Mauro Maccario, MD, Francesca Mallamaci, MD, Massimo Mannelli, MD, Mee-Jung Mattarello, MD, Angelica Moretti, MD, Gaetana Palumbo, MD, Gabriele Parenti, MD, Enzo Porteri, MD, Andrea Semplicini, MD, Damiano Rizzoni, MD, Ermanno Rossi, MD, Marco Boscaro, MD, Achille Gaspa Reviss, MD, PhD, Franco Mantero, MD, for the PAPY Study Investigators

*Padova, Ancona, Reggio Emilia, Pisa, L'[illegible]renze, Torino, and Reggio Calabria, Italy*

NO



**Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline**

John W. Funder, Robert M. Carey, Carlos Fardella, Celso E. Gomez-Sanchez, Franco Mantero, Michael Stowasser, William F. Young Jr., and Victor M. Montori*

J Clin Endocrinol Metab. September 2008, 93(9):3266–3281

## Case detection

1. Patients with Joint National Commission stage 2 (>160-179/ 100-109 mmHg) o con stage 3 (>180/110 mmHg)
2. Drug-resistant hypertension
3. Hypertension and hypokalemia
4. Hypertension with adrenal incidentaloma
5. Hypertension and family history of early-onset hypertension or cerebrovascular accident at a young age (<40 yrs)
6. Hypertensive first-degree relatives of patients with PA

Alcune linee guida cardiologiche inseriscono anche

- Patologia cardiaca non commisurata al grado dell'ipertensione

# Studio del Sistema Renina-Angiotensina-Aldosterone

**Attività plasmatica reninica (PRA)**

**Aldosterone plasmatico (Aldo p)**



**PRA**

**Aldo p**

**Ricercare cause di**

**Ipertensione secondaria**

- **Ipertensione renovascolare**
- **Uso di diuretici**
- **Tumore secernenti renina**
- **Ipertensione maligna**
- **Coartazione aortica**



**PRA**

**Aldo p**

**Aldo-PRA ratio ≥40**

**Aldo p≥15 ng/dl**

**Ricercare**

**Iperaldosteronismo**

**Primario**



**PRA**

**Aldo p**

**Valutare**

- **Iperplasia surrenalica congenita**
- **Tumori producenti DOC**
- **Sindrome di Cushing**
- **Deficit 11-ß-OHSDH**
- **Mutazioni attivanti MR**
- **Sindrome di Liddle**

# Effetti dell' Aldosterone

**Genomici e non genomici**



- Aterosclerosi vascolare
- Infiammazione

**Stroke**



- Fibrosi miocardica
- Ipertrofia
- Alterazioni ritmo
- Alterata funzione sistolica e diastolica

**CHD e scompenso cardiaco**



- Infiammazione
- Rimodellamento vascolare
- Ridotta vasodilataz.
- Disfunzione endotelio

**Aterosclerosi**





- Riduzione della sensibilità insulinica e alterato metabolismo glucidico

**Sindrome Metabolica**
**Alterazioni glucidiche e DM**



- Fibrosi renale
- Infiammazione

**Insufficienza renale**

Journal of the American College of Cardiology
© 2005 by the American College of Cardiology Foundation
Published by Elsevier Inc.

Vol. 45, No. 8, 2005
ISSN 0735-1097/05/$30.00
doi:10.1016/j.jacc.2005.01.015



# Evidence for an Increased Rate of Cardiovascular Events in Patients With Primary Aldosteronism

Paul Milliez, MD,* Xavier Girerd, MD, PHD,† Pierre-François Plouin, MD,‡ Jacques Blacher, MD, PHD,§ Michel E. Safar, MD,§ Jean-Jacques Mourad, MD, PHD‖

*Paris and Bobigny, France*

**Table 3.** Rate of Cardiovascular Events and Cardiac Structure in Primary Aldosteronism Patients and Controls

| | Primary Aldosteronism (n = 124) | Essential Hypertension (n = 465) | Odds Ratio (95% CI) | p Value |
|---|---|---|---|---|
| Stroke (%) | 12.9 | 3.4 | 4.2 (2.0–8.6) | <0.001 |
| Myocardial infarction (%) | 4.0 | 0.6 | 6.5 (1.5–27.4) | <0.005* |
| Atrial fibrillation (%) | 7.3 | 0.6 | 12.1 (3.2–45.2) | <0.0001* |
| Echocardiographic LVH (%) | 34 | 24 | 1.6 (1.1–2.5) | <0.01 |
| Electrocardiographic LVH (%) | 32 | 14 | 2.9 (1.8–4.6) | <0.001 |

*Fisher exact test.
CI = confidence interval; LVH = left ventricular hypertrophy.

# Alterazioni cardiache in corso di Iperaldosteronismo Primario



Myocite Hypertrophy

Myocardial Fibrosis






LVH

# Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension

Robert Holaj, Tomáš Zelinka, Dan Wichterle, Ondřej Petrák, Branislav Štrauch and Jiří Widimský Jr

Table 3 Intima–media thickness measurement

| | Primary aldosteronism ($n = 33$) | Essential hypertension ($n = 52$) | Controls ($n = 33$) | ANOVA |
|---|---|---|---|---|
| CCA IMT mean/max (mm) | $0.987 \pm 0.152^{*,\dagger\dagger}$ | $0.892 \pm 0.155^{\dagger}$ | $0.812 \pm 0.126$ | $< 0.0001$ |
| CB IMT mean/max (mm) | $1.157 \pm 0.243^{\dagger}$ | $1.131 \pm 0.275$ | $0.994 \pm 0.203$ | 0.03 |
| Combined IMT mean/max (mm) | $1.066 \pm 0.162^{\dagger\dagger}$ | $0.974 \pm 0.196^{\dagger}$ | $0.884 \pm 0.141$ | 0.0002 |

ANOVA, Analysis of variance; CB, carotid bifurcation; CCA, common carotid artery; IMT, intima–media thickness; $^{*}P < 0.01$ versus essential hypertension; $^{\dagger}P < 0.05$, $^{\dagger\dagger}P < 0.001$ versus controls.

Journal of Hypertension 2007, 25:1451–1457

# PREVALENZA



Primary Aldosteronism: Rare Bird or Common Cause of Secondary Hypertension?

*Michael Stowasser, MBBS, FRACP, PhD*

**Curr Hypertens Rep 2001**

Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Gian Paolo Rossi

Curr Hypertens Rep. 2004 Feb;6(1):1-4. Review.

# Sindrome  di Conn: rare bird

- Ipertensione arteriosa
- Ipokaliemia
- Alcalosi metabolica
- Adenoma surrenalico aldosterone-secernente



JW Conn
Primary aldosteronism,
a new clinical syndrome.
J Lab Clin Med 1955

# ARR = aldosterone / PRA

Hiramatsu Arch Int Med 1981

**L'applicazione dell'ARR ha aumentato drasticamente il numero di casi diagnosticati, maggioranza normokaliemici.**

## Iperaldosteronismi primari - Classificazione
## (11% delle ipertensioni)

| | | |
|---|---|---|
| 1. | Adenoma surrenalico<br>– monolaterale<br>– atipico | 30% |
| 2. | Iperaldosteronismo idiopatico<br>– micronodulare<br>– macronodulare | 65% |
| 3. | Iperplasia surrenalica primaria unilaterale | 3% |
| 4. | Iperaldosteronismo sopprimibile con glucocorticoidi (GRA) | <1% |
| 5. | Iperaldosteronismo familiare (FH-II) | ? |
| 6. | Carcinoma | 1% |
| 7. | Tumore extrasurrenalico (tumore ovarico) | <1% |

**Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol**

Gilberta Giacchetti[a], Vanessa Ronconi[a], Giulio Lucarelli[a], Marco Boscaro[a] and Franco Mantero[b]

## ROC curve analysis for upright ARR (♦)and supine ARR (●)




Cut-off

| | |
|---|---|
| A: 75 | a: 70 |
| B: 60 | b: 50 |
| C: 50 | c: 40 |
| D: 45 | d: 35 |
| **E: 40** | e: 30 |
| F: 35 | **f: 25** |
| G: 30 | g: 20 |
| H: 25 | h: 10 |
| I: 20 | i: 5 |

**SE: Sensitivity; SP: Specificity**

**J Hypertens 2006**

## Aldosterone /PRA: possibili interferenze

| | |
|---|---|
| **Dieta** | |
| – iposodica | probabili falsi negativi |
| – eccesso di sale | possibili falsi positivi |
| **Farmaci** | |
| – ß bloccanti | possibili falsi positivi |
| – calcioantagonisti | possibili falsi negativi |
| – Inibitori della renina | possibili falsi negativi |
| – ACE-inibitori | falsi negativi (molto improbabili) |
| – sartanici | possibili falsi negativi |
| – antialdosteronici | molto probabili falsi negativi |
| – diuretici | possibili falsi negativi |
| – a bloccanti | non effetti |




JCEM 93:3266-81,2008 (adattata e modificata)

# PA CONFIRMATORY TESTS

| Confirmatory test | Procedure | Interpretation | Concerns |
|---|---|---|---|
| Oral sodium loading test | Patients should increase their sodium intake to >200 mmol/d (~6 g/d) for 3 d, verified by 24-h urine sodium content. Patients should receive adequate slow-release potassium chloride supplementation to maintain plasma potassium in the normal range. Urinary aldosterone is measured in the 24-h urine collection from the morning of d 3 to the morning of d 4. | PA is unlikely if urinary aldosterone is lower than 10 μg/24 h (27.7 nmol/d) in the absence of renal disease where PA may coexist with lower measured urinary aldosterone levels. Elevated urinary aldosterone excretion [>12 μg/24 h (>33.3 nmol/d) at the Mayo Clinic, >14 μg/24 h (38.8 nmol/d) at the Cleveland Clinic] makes PA highly likely. | This test should not be performed in patients with severe uncontrolled hypertension, renal insufficiency, cardiac insufficiency, cardiac arrhythmia, or severe hypokalemia. The 24-h urine collection may be inconvenient. Laboratory-specific poor performance of the RIA for urinary aldosterone (aldosterone 18-oxo-glucuronide or acid-labile metabolite) may blunt diagnostic accuracy, a problem obviated by the currently available HPLC-tandem mass spectrometry methodology (52). Aldosterone 18-oxo-glucuronide is a renal metabolite, and its excretion may not rise in patients with renal disease. |
| SIT | Patients stay in the recumbent position for at least 1 h before and during the infusion of 2 liters of 0.9% saline iv over 4 h, starting at 0800–0930 h. Blood samples for renin, aldosterone, cortisol, and plasma potassium are drawn at time zero and after 4 h, with blood pressure and heart rate monitored throughout the test. | Postinfusion plasma aldosterone levels <5 ng/dl make the diagnosis of PA unlikely, and levels >10 ng/dl are a very probable sign of PA. Values between 5 and 10 ng/dl are indeterminate (57–60). | This test should not be performed in patients with severe uncontrolled hypertension, renal insufficiency, cardiac insufficiency, cardiac arrhythmia, or severe hypokalemia. |

# PA CONFIRMATORY TESTS

| Confirmatory test | Procedure | Interpretation | Concerns |
|---|---|---|---|
| FST | Patients receive 0.1 mg oral fludrocortisone every 6 h for 4 d, together with slow-release KCl supplements (every 6 h at doses sufficient to keep plasma $K^+$, measured four times a day, close to 4.0 mmol/liter), slow-release NaCl supplements (30 mmol three times daily with meals) and sufficient dietary salt to maintain a urinary sodium excretion rate of at least 3 mmol/kg body weight. On d 4, plasma aldosterone and PRA are measured at 1000 h with the patient in the seated posture, and plasma cortisol is measured at 0700 and 1000 h. | Upright plasma aldosterone >6 ng/dl on d 4 at 1000 h confirms PA, provided PRA is < 1 ng/ml·h and plasma cortisol concentration is lower than the value obtained at 0700 h (to exclude a confounding ACTH effect) (42, 43, 56, 61–63). | Although some centers (10, 16) conduct this test in the outpatient setting (provided that patients are able to attend frequently to monitor their potassium), in other centers, several days of hospitalization are customary.<br>Most of the data available come from the Brisbane group (42, 43, 56, 61–63) who have established, on the basis of a very large series of patients, a cutoff of a plasma aldosterone concentration of 6 ng/dl at 1000 h in an ambulatory patient on d 4.<br>Proponents of the FST argue that 1) it is the most sensitive for confirming PA, 2) it is a less intrusive method of sodium loading than SIT and therefore less likely to provoke non-renin-dependent alterations of aldosterone levels, 3) it allows for the potentially confounding effects of potassium to be controlled and for ACTH (via cortisol) to be monitored and detected, and 4) it is safe when performed by experienced hands. |
| Captopril challenge test | Patients receive 25–50 mg captopril orally after sitting or standing for at least 1 h. Blood samples are drawn for measurement of PRA, plasma aldosterone, and cortisol at time zero and at 1 or 2 h after challenge, with the patient remaining seated during this period. | Plasma aldosterone is normally suppressed by captopril (>30%). In patients with PA, it remains elevated and PRA remains suppressed. Differences may be seen between patients with APA and those with IHA, in that some decrease of aldosterone levels is occasionally seen in IHA (23, 64–66). | There are reports of a substantial number of false-negative or equivocal results (67, 68). |

# SOTTOTIPI

**Iperplasia surrenalica bilaterale (IHA)** **TERAPIA MEDICA**

**Adenoma aldosterone-secernente (APA)** **TERAPIA CHIRURGICA**

**Iperplasia surrenalica unilaterale (PAH)** **TERAPIA CHIRURGICA**

**Carcinoma surrenalico** **TERAPIA CHIRURGICA**

**FORME FAMILIARI**

**Iperaldosteronismo familiare di tipo I (GRA)**

**Iperaldosteronismo familiare di tipo II (FH-II)**

**Iperaldosteronismo familiare di tipo III (FH-III)**

**In condizione di riposo la cellula della granulosa è iperpolarizzata**



# L’interazione dell’ATII con il recettore…



# Mutazioni somatiche nell'adenoma producente aldosterone



# Iperaldosteronismo familiare

| Overview of Familial Hyperaldosteronism (FH)[a] | | | | |
|---|---|---|---|---|
| **FH Type** | **Inheritance** | **Associated Gene** | **Clinical Features** | **Pathologic Features** |
| FH-I | Autosomal dominant | *CYP11B1*, *CYP11B2* | Early onset (often before age 20 y), resistant hypertension, mostly normokalemic, complete aldosterone response to dexamethasone | Normal adrenal glands; occasional adrenal cortical nodular disease or bilateral hyperplasia |
| FH-II | Autosomal dominant; undetermined in some cases | Unknown; linked to 7p22 | Clinical features indistinguishable from sporadic primary aldosteronism: onset in adulthood, resistant hypertension, mostly normokalemic | Adrenal cortical adenoma or bilateral hyperplasia |
| FH-III | Autosomal dominant | *KCNJ5* | Very early onset (childhood), severely resistant hypertension, hypokalemia, very high aldosterone concentrations (2–10 times normal concentrations) | Marked bilateral adrenal hyperplasia; occasional normal adrenal glands |


LDL
HDL
StAR
CHOLESTEROL
Cholesterol side chain cleavage
PREGNENOLONE
3β-hydroxysteroid dehydrogenase
PROGESTERONE
21 hydroxylase
DOC
11β-hydroxylase
CORTICOSTERONE
Aldosterone synthase
ALDOSTERONE
MINERALOCORTICOID
17α-hydroxylase/ 17,20 lyase
17-OH-PREGNENOLONE
3β-hydroxysteroid dehydrogenase
17-OH-PROGESTERONE
21 hydroxylase
11-DEOXYCORTISOL
11β-hydroxylase
CORTISOL
GLUCOCORTICOID
17α-hydroxylase/ 17,20 lyase
DHEA
A'DIONE
ANDROGENS


Familial hyperaldosteronism
(~5% of cases)
FHx (?)
FH1
(Cyp11B2/B1)
CACNA1D
FH3 (KCNJ5)
FH2 (7p22)
Germline mutations
Sporadic hyperaldosteronism
(95% of cases)
KCNJ5
CACNA1D
ATP1A1
ATP2B3
BAH
LOH?
Other?
APA
Somatic mutations in APA

## Diagnosi di sottotipo – Imaging

**TC STRATO SOTTILE (con mdc, sezioni 2.5-3 mm)**

- esame di prima scelta
- scarsa sensibilità diagnosi di microadenoma (25%)
- sensibilità 50% specificità 58%

(Magill SB, JCEM 2001; Harper R, QJM 1999)

**RMN**

- sensibilità inferiore rispetto alla TC
- solo macroadenomi

**SCINTIGRAFIA con 6-b-[$^{131}$I]-iodometil-19-norcolesterolo (NP-59) + soluz. Lugol + DEX**

- frequenti falsi + o risultati dubbi

## Diagnosi di sottotipo (APA-IHA)

**Cateterismo venoso surrenalico: prelievo di sangue refluo vv. surrenaliche, vv. renali, cava**

Vena surrenalica dx



Vena surrenalica sn

Problemi aperti
-A tutti?
-Incannulamento
-simultaneo?
- Stimolo con ACTH?

**- Gold standard**

**- v. surrenalica dx: difficoltà cateterizzazione**

**- aldosterone/cortisolo ratio**

# Iperaldosteronismo Primario



# Antiagonisti del recettore dei mineralocorticoidi (antialdosteronici)




Spironolactone

Sulfur Metabolites




Canrenone

$K^+ + H_2O$




$K^+$- Canrenoate




Eplerenone

## ANTAGONISTI RECETTORIALI DELL'ALDOSTERONE

| | SPIRONOLATTONE | EPLERENONE |
|---|---|---|
| Meccanismo d'azione | Antagonista competitivo dei recettori dell'aldosterone | Antagonista competitivo dei recettori dell'aldosterone |
| Selettività | Non selettivo | Selettivo |
| Altre azioni steroidee | - Attività progestinica<br>- Attività antiandrogena | |
| Effetti collaterali | - Irregolarità ciclo mestruale<br>- Ginecomastia<br>- Impotenza | non effetti collaterali steroido-correlati |